This is a contrast between CRISPR Therapeutics AG (NASDAQ:CRSP) and Galectin Therapeutics Inc. (NASDAQ:GALT) based on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
|Galectin Therapeutics Inc.||3||0.00||41.34M||-0.39||0.00|
Demonstrates CRISPR Therapeutics AG and Galectin Therapeutics Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 represents CRISPR Therapeutics AG (NASDAQ:CRSP) and Galectin Therapeutics Inc. (NASDAQ:GALT)’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,235,636.97%||-2.6%||-2%|
|Galectin Therapeutics Inc.||1,218,534,457.35%||-74%||-60.8%|
CRISPR Therapeutics AG’s Current Ratio is 8.3 while its Quick Ratio is 8.3. On the competitive side is, Galectin Therapeutics Inc. which has a 41.5 Current Ratio and a 41.5 Quick Ratio. Galectin Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to CRISPR Therapeutics AG.
The following table shown below contains the ratings and recommendations for CRISPR Therapeutics AG and Galectin Therapeutics Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Galectin Therapeutics Inc.||0||0||0||0.00|
CRISPR Therapeutics AG’s consensus target price is $72, while its potential upside is 8.60%.
Institutional & Insider Ownership
Institutional investors held 46.8% of CRISPR Therapeutics AG shares and 16.6% of Galectin Therapeutics Inc. shares. Insiders held 0.4% of CRISPR Therapeutics AG shares. Comparatively, 0.3% are Galectin Therapeutics Inc.’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Galectin Therapeutics Inc.||-7.43%||-22.54%||-20.48%||-20.27%||-40.91%||-12.83%|
For the past year CRISPR Therapeutics AG has 153.31% stronger performance while Galectin Therapeutics Inc. has -12.83% weaker performance.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The companyÂ’s lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.